

Simpson Thacher Represents Alvogen and Pamplona in the Sale of a Controlling Stake in Alvogen

06.22.15



The Firm represented Alvogen and Pamplona Capital Management ("Pamplona") in connection with Pamplona's sale of a controlling stake in Alvogen to a consortium of investors led by CVC Capital Partners.

Alvogen is an international, privately owned pharmaceuticals company focused on developing, manufacturing and selling generic, brand, over-the-counter brands and biosimilar products.

The Simpson Thacher team included Michael T. Holick, Michael Guo and Michael Chao (M&A – New York); Clare Gaskell and Charles Leeming (M&A – London); Brian Steinhardt and Brian Gluck (Credit); Michael Naughton and Philip Mirrer-Singer (Competition); Devin Heckman (Tax); Brian Robbins, Andrew Blau and Patricia Adams (Executive Compensation and Employee Benefits); Noah Leibowitz and Genevieve Dormont (Intellectual Property); and Adeeb Fadil and Louise Kruger (Environmental).

Team and Contacts

Michael Holick

Partner

mholick@stblaw.com

+1-212-455-3733

Clare Gaskell

Partner

cgaskell@stblaw.com

+44-(0)20-7275-6181

Brian Gluck

Partner

bgluck@stblaw.com

Michael Chao

Partner

michael.chao@stblaw.com

+1-212-455-7183

Brian Steinhardt

Partner

bsteinhardt@stblaw.com

+1-212-455-3802

Brian Robbins

Partner

brobbins@stblaw.com

+1-212-455-2368

+1-212-455-3090

Andrew Blau

Partner

andrew.blau@stblaw.com

+1-212-455-2380

